Company Description
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China.
The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets.
It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases.
The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
It offers its products through distributors, its network of sales offices, and sales representatives.
The company is based in Haikou, the People's Republic of China.
| Country | China |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Ms. Zhilin Li |
Contact Details
Address: 2nd Floor, No. 17, Jinpan Road, Haikou Hainan Province, F4 570216 China | |
| Phone | 8689866811730 |
| Website | chinapharmaholdings.com |
Stock Details
| Ticker Symbol | CPHI |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001106644 |
| CUSIP Number | 16941T104 |
| ISIN Number | US16941T2033 |
| Employer ID | 73-1564807 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhilin Li | President, Chief Executive Officer, Chairman and Interim Chief Financial Officer |
| Huang Na C.F.A. | BOD Secretary and IR Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |
| Feb 14, 2024 | EFFECT | Notice of Effectiveness |
| Feb 8, 2024 | 8-K | Current Report |
| Feb 6, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jan 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | UPLOAD | Filing |
| Jan 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |